Familial Breast Cancer in China

ConditionsBreast Carcinoma Genetic Variation

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexFemale

Age18-75

SponsorCancer Institute and Hospital, Chinese Academy of Medical Sciences

About this trial

This study is a retrospective descriptive study to collect clinical data (mainly including medical records and follow-up information, etc.) of breast cancer patients with genetic variation who were first diagnosed and treated in a number of hospitals in China during the period from January 1, 2015 to December 31, 2024, and to establish a retrospective cohort of familial hereditary breast cancer. To analyze the clinical features, diagnosis and treatment and survival prognosis of patients with familial hereditary breast cancer. To explore the main factors affecting clinical diagnosis and treatment and survival prognosis of patients

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Familial inherited breast cancer with genetic variants, including but not limited to mutations in the BRCA1, BRCA2, TP53, and PALB2 genes

The patient had no major organ dysfunction

ECOG score 0-1

Disqualifiers

There are serious dysfunction of vital organs (heart, liver, kidney)

Patients with other malignancies, except cured non-melanoma skin cancer, cervical carcinoma in situ and other tumors that have been cured for at least 5 years

In other acute infectious disease or chronic infectious disease activity period

A history of uncontrolled seizures, central nervous system disorders, or mental disorders

Trial population

From January 1, 2015 to December 31, 2024, a number of hospitals in China first diagnosed and treated breast cancer patients with genetic variants

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

Genetic variation
Other intervention
To observe and describe the clinical features, diagnosis and treatment plan and survival prognosis of familial hereditary breast cancer in China, and explore the main factors affecting prognosis.

Treatment groups

500 Participants

are divided into 1 treatment group

Group A: Familial breast cancer1 intervention

Trial outcomes

Primary outcomes

Overall survival rate

Time frame

5-year

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: